ClinicalTrialsFinder
RecruitingPhase 2NCT07671534

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

GEMINI: Phase II Study Using Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

Sponsor

Sarcoma Oncology Research Center, LLC

Enrollment

60 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Cancer

Summary

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Gemcitabine, a drug called Mitomycin C, and others for people with solid tumor cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGemcitabine

600 mg/m2 (Max: 1000 mg) i.v. on D1, D8, D15

DRUGMitomycin C

Mitomycin C 14 mg i.v. every 6 weeks

DRUGThalidomide

Thalidomide 100 mg daily x 15 days

Locations(1)

Sarcoma Oncology Research Center / Cancer Center of Southern California

Santa Monica, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07671534

Related Trials

Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors

NCT075836541 location

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT073375254 locations

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT0719351111 locations

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT068021721 location

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT066076921 location